These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 35121001)

  • 1. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
    Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM
    Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
    Shrestha DB; Budhathoki P; Khadka S; Shah PB; Pokharel N; Rashmi P
    Virol J; 2020 Sep; 17(1):141. PubMed ID: 32972430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
    Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
    Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
    Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
    Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
    McMahon JH; Lau JSY; Roney J; Rogers BA; Trubiano J; Sasadeusz J; Molton JS; Gardiner B; Lee SJ; Hoy JF; Cheng A; Peleg AY
    Trials; 2020 Oct; 21(1):847. PubMed ID: 33050947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
    Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
    CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
    Furuta Y; Gowen BB; Takahashi K; Shiraki K; Smee DF; Barnard DL
    Antiviral Res; 2013 Nov; 100(2):446-54. PubMed ID: 24084488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
    Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
    Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections.
    Shiraki K; Daikoku T
    Pharmacol Ther; 2020 May; 209():107512. PubMed ID: 32097670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.
    Luvira V; Schilling WHK; Jittamala P; Watson JA; Boyd S; Siripoon T; Ngamprasertchai T; Almeida PJ; Ekkapongpisit M; Cruz C; Callery JJ; Singh S; Tuntipaiboontana R; Kruabkontho V; Ngernseng T; Tubprasert J; Abdad MY; Keayarsa S; Madmanee W; Aguiar RS; Santos FM; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Imwong M; Taylor WRJ; Chotivanich V; Chotivanich K; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    BMC Infect Dis; 2024 Jan; 24(1):89. PubMed ID: 38225598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
    Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
    Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques.
    Guedj J; Piorkowski G; Jacquot F; Madelain V; Nguyen THT; Rodallec A; Gunther S; Carbonnelle C; Mentré F; Raoul H; de Lamballerie X
    PLoS Med; 2018 Mar; 15(3):e1002535. PubMed ID: 29584730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.
    Takahashi H; Iwasaki Y; Watanabe T; Ichinose N; Okada Y; Oiwa A; Kobayashi T; Moriya M; Oda T
    Int J Infect Dis; 2020 Nov; 100():283-285. PubMed ID: 32829044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.